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Abstract
Background: Nasopharyngeal carcinoma (NPC) is a common epithelial neoplasm among the
Chinese populations in Southern China and South East Asia. Epstein-Barr virus (EBV) is known to
be an important etiologic agent of NPC and the viral gene products are frequently detected in NPC
tissues along with elevated antibody titres to the viral proteins (VCA and EA) in a majority of
patients. Elevated plasma EBV DNA load is regarded as an important marker for the presence of
the disease and for the monitoring of disease progression. However, other serum/plasma
parameters such as the levels of certain interleukins and growth factors have also been implicated
in NPC. The objectives of the present study are, 1) to investigate the correlations between plasma
EBV DNA load and the levels of interleukin (IL)-6, IL-10, TGF-β1 and SCF (steel factor) and 2) to
relate these parameters to the stages of NPC and the effect of treatment.
Methods: A total of 78 untreated NPC patients were enrolled in this study. Of these, 51 were
followed-up after treatment. The remaining patients had irregular or were lost to follow-up. Plasma
EBV DNA was quantified using real-time quantitative PCR. The levels of plasma interleukins and
growth factors were quantified using ELISA.
Results: A significant decrease in EBV DNA load was detected in plasma of untreated NPC
patients (1669 ± 637 copies/mL; n = 51) following treatment (57 ± 37 copies/mL, p < 0.05); n =
51). Plasma EBV DNA load was shown to be a good prognosticator for disease progression and
clinical outcome in five of the follow-up patients. A significant difference in IL-6 levels was noted
between the untreated patients (164 ± 37 pg/mL; n = 51) and following treatment (58 ± 16 pg/mL,
p < 0.05; n = 51). Positive correlations between EBV DNA load and IL-10 (r(49) = 0.535, p < 0.01),
between IL6 and IL-10 (r(49) = 0.474, p < 0.01) and between TGF and SCF (r(49) = 0.464, p < 0.01)
were observed in patients following treatment. None of the parameters tested including IgA-VCA
were associated with tumour stages.
Conclusion: We conclude that among the parameters investigated, EBV DNA load and IL-6 levels
were promising markers for the presence of NPC and for the assessment of treatment outcome.
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Background
Nasopharyngeal carcinoma (NPC) is rarely reported in
the West but occurs in high frequencies in Southern
China, Hong Kong, Taiwan, Singapore and Malaysia [1,2].
In Malaysia for the year 2003, NPC was the second major
cause of cancer mortality among males and ranked twelfth
among females. The frequencies NPC in males and
females were, respectively, 8.8% and 2.5% of the total
cases of cancers reported. NPC is an epithelial neoplasm
arising from the fossa of Rosenmuller situated at the post-
nasal space [3]. NPC is classified into three histological
types with the WHO Type II being more prevalent in Asia
and is strongly associated with Epstein-Barr virus (EBV)
[4]. EBV has been implicated as an important aetiological
agent for NPC with most patients demonstrating elevated
levels of IgA to the viral capsid antigen (VCA) and early
antigens (EA). A serum profile that shows elevated anti-
body titres to these viral proteins usually presents a signif-
icant positive diagnosis for the presence of malignancy
[5]. Cell-free EBV DNA has been shown to be a promising
prognosis marker especially for the monitoring of NPC.
Using real-time quantitative PCR, plasma EBV DNA was
found to be significantly elevated in up to 96% of NPC
patients compared to only 7% in the controls [6]. There
have been scanty but emerging reports on the importance
of immuno-modulatory cytokines and growth factors in
NPC. Most of these investigations attempted to relate the
expression of cytokines and their respective receptors to
the outcome and prognostication of NPC [7-9]. The
knowledge on the expression and functions of certain
cytokines in relation to NPC might be able to explain the
lack of an effective tumour-specific immune response
despite the induction of EBV-specific humoral and cyto-
toxic response in NPC patients. Some of the cytokines and
growth factors that are known to be important in NPC
include interleukin (IL)-6, IL-8, IL-10 and transforming
growth factor, beta-1 (TGF-β1). It would be interesting to
reconcile the presence of plasma EBV DNA to the levels of
these cytokines and growth factors and to determine if
there are any associations between these parameters and
the status of disease.
This present study investigated the concentrations of five
plasma factors – EBV DNA, IL-6, IL-10, TGF-β1 and SCF
(steel factor) – in NPC patients before and following treat-
ment. The data obtained indicated a discrepancy in the
levels of these factors in NPC patients before and after
treatment and in relation to healthy individuals.
Methods
Biological and clinical samples
The Namalwa cell line was cultured in RPMI-1640 supple-
mented with 10% (v/v) FCS and 300 mg/L L-glutamine.
The genome of each cell contains two integrated copies of
the EBV episomal DNA. Total DNA extracted from the
Namalwa cells was used as quantitative standards in the
real-time PCR assay. A conversion factor of two EBV cop-
ies per 6.6 pg of genomic DNA was used.
Peripheral blood was collected in a tube containing EDTA
to facilitate the subsequent separation of plasma. Blood
samples were collected from 78 untreated, pathologically
confirmed NPC patients when they first presented at the
NCI Cancer Hospital from January 2003 to January 2005
after informed consent was obtained. Tumours were
staged according to the AJCC/UICC (1997) classification
system. Samples were also collected from 51 of the 78
patients following treatments consisting of radio- and
chemotherapy. As controls, 39 blood samples from age
and sex-matched healthy individuals were obtained from
the University of Malaya Medical Centre (UMMC) organ
matching laboratory. Plasma isolation was performed for
each sample immediately upon receipt in the laboratory,
aliquoted and stored at -20°C until use. Plasma samples
of patients and controls were titrated for the IgA anti-EBV
VCA antibody using indirect immunofluorescence (IFA).
This study was approved by scientific and ethical commit-
tees of NCI Cancer Hospital and UMMC respectively.
DNA extraction
DNA was extracted from plasma samples and the
Namalwa cells using the QIAamp® DNA minikit (Qiagen,
USA) following the manufacturer's instructions. A 200 μL
aliquot of plasma from each sample or suspension con-
taining 1.0 × 107 Namalwa cells was used for DNA extrac-
tion. From this point onwards, all samples were processed
according to the manufacturer's instructions. The
extracted DNA was quantified and checked for purity
using a spectrophotometer (Shimadzu, Japan).
Real-time quantitative PCR
Quantification of EBV DNA load in plasma was per-
formed using the iCycler iQ™ Real-time PCR system (Bio-
Rad, USA). The quality of purified DNA from plasma sam-
ples was validated by conventional PCR amplification of
the humanβ-globin gene using gene-specific primers (βF:
5'-AGGAGTGGTGGCTCATGTCT-3' andβR: 5'-CTCAAG-
GGATCCTCCCATTT-3'). Primers flanking the BamH1W
region (EBV coordinate: 14649–14724) of the EBV
genome and TaqMan® probe (Applied Biosystems, USA)
directed within this flanked region (EBV coordinate:
14672–14698) were reported by Lo and co-workers [6]
and were custom-made (Applied Biosystems, USA). An
aliquot of five μL of purified DNA isolated from the
plasma was used for amplification in a total reaction vol-
ume of 50 μL, which contained the following compo-
nents; 300 nM of each primer, 25 nM of TaqMan® probe
and TaqMan® PCR Reagents consisting of 4 mM MgCl2,
200 μM of each dATP, dCTP and dGTP; 400 μM of dUTP;
0.5 U AmpErase uracil N-glycosylase (UNG) and 1.25 UBMC Cancer 2006, 6:227 http://www.biomedcentral.com/1471-2407/6/227
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AmpliTaq Gold (Applied Biosystems, USA). Amplifica-
tion reaction for each sample and standard was performed
in duplicates. The standard curve correlating the viral
DNA copy to threshold cycle was constructed by amplify-
ing five μL aliquots of serially diluted DNA isolated from
Namalwa cells that contained 45, 450, 45000, 100000
and 450000 EBV DNA copies per mL. To assess the inter-
assay reproducibility of our RTQ-PCR assay, the Namalwa
DNA standards in five logs of concentration as mentioned
were amplified in triplicates on four separate days.
Amplification cycling was initiated by incubation at 50°C
for 2 minutes for UNG activation and initial denaturation
at 95°C for 8 minutes, followed by 40 cycles of 95°C for
30 seconds and 56°C for one minute. A standard curve
was only accepted if the correlation coefficient is 0.996 or
higher and its slope ranged between -3.74 to -3.32, which
correlated to amplification efficiency of between 85 to
100% respectively. The fluorescence detection threshold
value was set at 10× the mean standard deviation of fluo-
rescence in all reactions. EBV DNA load, expressed as viral
copy number per mL of plasma, was determined using the
equation below.
EBV DNA copy/mL = Q (VE/VA) *1/VP
Q: DNA copy determined from standard curve; VE: Vol-
ume of DNA eluent (50 μL); VA: Volume of DNA template
amplified (five μL); VP: Volume of plasma used for DNA
extraction (200 μL).
Indirect Immunofluorescence Assay (IFA)
The expression of VCA was induced in P3HR-1 cells using
20 ng/ml of 12-O-tetradecanoyl phorbol 13-acetate (TPA,
Sigma) and 3 mM sodium butyrate (NBA, Merck). The
induced P3HR-1 cells were fixed on Teflon-coated multi-
wells slides in cold acetone and dried. The fixed cells in
each well was incubated with a serially diluted serum sam-
ple and later, challenged with fluorescein-conjugated goat
anti-human IgA antibody that allowed indirect detection
of VCA-specific antibody using a UV-microscope (200×
magnification). A sample was considered IgA-VCA posi-
tive when more than 10% of the induced P3HR-1 cells
showed specific fluorescence. Non-specific fluorescence
staining was cross-checked with the EBV-negative BJAB
cells. Negative and positive sera with respect to VCA were
included in every assay.
Enzyme-linked immunosorbent assay (ELISA)
The concentrations of IL-6, IL-10, activated TGF-β1 and
SCF in the plasma were determined using the BD OptEIA
ELISA Set (BD Biosciences, USA) for each individual
cytokine and growth factor following the manufacturer's
protocol. Briefly, a 96-well flat bottom Nunc Maxisorp™
(Nalge Nunc Intl., USA) was coated with capture antibody
specific to the cytokine or growth factor of interest. The
plate was washed and blocked before 100 μL of plasma
and serially diluted specific standards were added to the
respective wells. Following a series of stringent washing,
the captured cytokine or growth-factor was detected using
the specific HRP-conjugated detection antibody. The sub-
strate reagent was added into each well and following col-
our development, the plate was read at 630 nm
wavelength using an ELISA plate reader.
Statistical analyses
All statistical analyses were preformed using the program,
SPSS (Statistical Program for Social Sciences; SPSS Inc,
USA). The means of different plasma cytokine/growth fac-
tor levels and EBV DNA load in untreated and treated
NPC patients and healthy control was compared using
One-way ANOVA. Bonferroni and Dunnett C methods
were employed as the post-hoc tests when the means
between the groups of interest were found to be signifi-
cant by the ANOVA F test. Paired-sample t test was used to
compare the means of cytokine levels and EBV load in
NPC patients before and after treatment. Pearson correla-
tions were used to determine the relationship between
EBV DNA load and different cytokine/growth factor lev-
els. Bivariate linear regression was employed in assessing
the associations between plasma EBV load and cytokine
levels (as the dependent variables), and tumour stage and
IgA-VCA titres (as the independent variables). ANOVA F
and t tests were used to determine the significance of the
associations between the independent and dependent var-
iables.
Results
Tumour stages and EBV serology
Tumours were staged according to the AJCC/UICC (1997)
classification system. The distribution of the 78 untreated
NPC patients according to tumour stages was as follows:
five stage I, two stage IIA, 17 stage IIB, 14 stage III, one
stage IIIB, 19 stage IVA, 19 stage IVB and one stage IVC.
Due to significant disparity in the number of patients in
different tumour subgroups, patients belonging to sub-
groups of a particular stage were combined forming only
four major groups consisting of stages I, II, III and IV. All
patients were seropositive for EBV with IgA-VCA titres
ranging from 5 to 80 (median titre = 20), whereas all the
39 controls had IgA-VCA titres < 5.
Plasma EBV load, tumour stages and IgA-VCA titres
A comparison was made between the plasma EBV DNA
load in 51 NPC patients before and following treatment
(Table 1). Of the 51 patients, 34 patients showed signifi-
cant reductions in viral DNA load following treatments. A
mean DNA load of 1669 ± 637 copies/mL was detected
before treatment and was reduced to 57 ± 37 copies/mL
after treatment [t(33) = 2.566, p < 0.05] (Figure 1). In
eight of the 51 patients, increases in EBV DNA loads fol-BMC Cancer 2006, 6:227 http://www.biomedcentral.com/1471-2407/6/227
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lowing treatments were noted. However, the difference in
mean viral loads before (559 ± 436 copies/mL) and after
(13600 ± 12773 copies/mL) treatment in these eight
patients was statistically insignificant due to large stand-
ard variation. Interestingly, the remaining nine patients
had undetectable plasma EBV loads both before and after
treatment. All the 39 healthy controls had undetectable
plasma EBV load.
Next, we assessed the relationship between the stages of
tumour and plasma EBV load. EBV load was quantified in
the plasma samples of 78 untreated NPC patients com-
prising of five stage I, 19 stage II, 15 stage III, and 39 stage
IV. Regression analysis failed to show significant associa-
tions between these two variables indicating that the
plasma EBV DNA load was not a marker of tumour stage
[r2 = 0.012; F(1,76) = 0.935, p = 0.337]. The 78 NPC sam-
ples were then grouped according to their IgA-VCA titres,
and the plasma EBV load was determined for each titre
group. There was also no association between plasma IgA-
VCA titre and EBV load [r2 = 0.004; F(1,71) = 0.281, p =
0.598].
Plasma cytokines levels, tumour stages and IgA-VCA titres 
in untreated NPC patients and following treatments
The plasma levels of cytokines and growth factors – IL-6,
IL-10, TGF-β1 and SCF in NPC patients, both before and
after treatments, were determined using quantitative cap-
ture ELISA (Table 1). The cytokines, IL-6 and IL-10 have
been widely investigated in solid tumours as being impor-
tant prognostic factors [10]. Untreated NPC patients had
a mean IL-6 concentration of 164 ± 37 pg/mL, which was
significantly higher than the mean value following treat-
ment (58 ± 16 g/mL; F(2,138) = 7.534, p < 0.01). The
mean IL-6 concentration in NPC patients after treatment
compared favourably with the level detected in healthy
controls (mean = 32 ± 13 pg/mL; Figure 2A). There were
no observable variations in the levels of plasma IL-10
between NPC patients, treated or otherwise and healthy
controls (Figure 2B).
The level of TGF-β1 in untreated NPC patients (2020 ±
384 pg/mL) was found to be significantly lower than the
healthy controls (6368 ± 682 pg/mL; p < 0.05). The same
patients recorded an increase in mean TGF-β1 following
treatment (4034 ± 2110 pg/mL; Figure 2C) although the
difference does not differ significantly from the level
before treatment (at α = 0.05).
The expression SCF or steel factor (Sl) receptor, c-kit, has
been reported in NPC patients and is known to be con-
fined only to the EBV-positive tumour cells [11]. SCF was
found to be reduced in untreated NPC patients (532 ± 102
pg/mL) as compared to the level in healthy controls (1115
± 193 pg/mL; F(2,138) = 4.823, p = 0.009). The level of
SCF among the controls in this study compares favourably
with the level of 1565 ± 352 pg/mL reported by Tao and
co-workers [12] in their cohort of healthy individuals.
There was no significant change in SCF level among the
Box and whisker plot representing EBV DNA load in 34 NPC  patients who experienced significant decrease in plasma viral  DNA load following treatment (t(33) = 2.566, p < 0.05) Figure 1
Box and whisker plot representing EBV DNA load in 34 NPC 
patients who experienced significant decrease in plasma viral 
DNA load following treatment (t(33) = 2.566, p < 0.05). Pre-
treatment EBV DNA load is 1669 ± 637 copies/mL (median = 
243 copies/mL) as compared to 57 ± 37 copies/mL post-
treatment (median = 0 copies/mL).
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Table 1: Comparison of mean plasma EBV DNA load and cytokine levels between NPC patients and controls.
Plasma Factors NPC Patients (mean ± SE) Healthy Controls (mean ± SE; n = 39)
Untreated (n = 51) Treated (n = 51)
EBV Load (copy/ml) 1669 ± 637 57 ± 37 0 ± 0
IL-6 (pg/ml) 164 ± 37 58 ± 16 31 ± 13
IL-10 (pg/mL) 4 ± 4 15 ± 9 9 ± 5
TGF-β1 (pg/mL) 2020 ± 384 4034 ± 2110 6368 ± 683
SCF (pg/mL) 532 ± 102 581 ± 133 1115 ± 193
Plasma samples from NPC patients, both pre- and post-treatment, and healthy controls were analyzed for the EBV DNA load, IL-6, IL-10, TGF-β1 
and SCF levels. Data represents mean ± SE. Differences in means that are of statistical significance are explained in the text.BMC Cancer 2006, 6:227 http://www.biomedcentral.com/1471-2407/6/227
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same NPC patients following treatment (581 ± 315 pg/
mL; p = 0.963; Figure 2D).
When the level of each cytokine and growth factor was
compared against the patients' IgA-VCA titres, no statisti-
cally significant association was found indicating that the
plasma concentrations of IL-6, IL-10, TGF-β1 and SCF
were independent of VCA antibody titres. Similarly, none
of the cytokines tested showed any association with the
stages of tumour.
Plasma EBV load and cytokines levels
None of the cytokines tested had any significant correla-
tions with plasma EBV DNA load in the 75 untreated NPC
patients. Data from the other three patients were unavail-
able as their plasma samples were insufficient. However,
among 51 of the 75 NPC patients who had been treated,
significant positive correlations were found between EBV
load and IL-10 [r(49) = 0.535, p < 0.01], IL-6 and IL-10
[r(49) = 0.474, p < 0.01], and between TGF-β1 and SCF
[r(49) = 0.464, p < 0.01]. None of these correlations was
Plasma levels of (A) IL-6, (B) IL-10, (C) TGF-β1 and (D) SCF in 51 NPC patients, both before and after treatment, and 39  healthy controls Figure 2
Plasma levels of (A) IL-6, (B) IL-10, (C) TGF-β1 and (D) SCF in 51 NPC patients, both before and after treatment, and 39 
healthy controls. Quantification of cytokines and growth factors was performed using the BD OptEIA ELISA Set (BD Bio-
sciences, USA). Bars indicate means and SE. Differences in means that are of statistical significance are as explained in the text.
A
C
NPC (untreated) NPC (treated) Healthy
T
G
F
-
b
e
t
a
 
1
 
(
p
g
/
m
L
)
0
2000
4000
6000
8000
10000
NPC (untreated) NPC (treated) Healthy
I
L
-
6
 
(
p
g
/
m
l
)
0
50
100
150
200
250
NPC (untreated) NPC (treated) Healthy
S
C
F
 
(
p
g
/
m
L
)
0
500
1000
1500
2000
NPC (untreated) NPC (treated) Healthy
I
L
-
1
0
 
(
p
g
/
m
L
)
0
10
20
30
40
50
D
BBMC Cancer 2006, 6:227 http://www.biomedcentral.com/1471-2407/6/227
Page 6 of 8
(page number not for citation purposes)
observed either in the untreated NPC patients or in the
healthy controls. The correlation between plasma IL-6
and IL-10 levels was also demonstrated in patients with
non-Hodgkin's lymphoma (El-Far et al., 2004) and post-
transplant lymphoproliferative disorder [13].
IgA-VCA, EBV load and their clinical correlations
Five of the 78 NPC patients consented to have their blood
samples taken during their initial presentations before
receiving any form of treatments and at each subsequent
visit when they returned to be treated. Treatments typi-
cally consisted of radiotherapy and/or chemotherapy (5-
FU and cisplatin). Two of the five patients (NPC18 and
NPC22) were presented with stage IIB tumours and had
persistently high IgA-VCA titres and high plasma EBV
load. A total of eight and six consecutive samples were col-
lected from NPC18 and NPC22 respectively. Patient
NPC18 had IgA-VCA titre of 80 before treatment and fluc-
tuated between 40 and 80 during his subsequent visits.
This patient also had detectable EBV load of 195 copies/
mL during his initial presentation but escalated to a few
thousand-fold peaking at 406,000 copies/mL in one of
the subsequent visits. Patient NPC22 had similar IgA-VCA
and plasma EBV load profiles as NPC18 but the EBV load
peaked at 52,000 copies/mL in one subsequent visit. Both
patients succumbed to their diseases and died due to dis-
ease progression.
In another two patients, NPC41 and NPC80, who were
presented with tumour grades IVB and IIB respectively,
persistently high IgA-VCA titres during their initial presen-
tations and in the consecutive samples were detected. The
IgA-VCA titres fluctuated between 40 and 80 in patient
NPC41 but maintained at 80 throughout in patient
NPC80. Interestingly, patient NPC41 recorded a very low
plasma EBV DNA load during his first presentation (74
copies/mL) and had undetectable viral load during subse-
quent treatment work-ups. On the other hand, patient
NPC80 had undetectable viral DNA load during his first
presentation and in subsequent visits. In all, four consec-
utive samples each were collected from NPC41 and
NPC80. Both patients survived and responded well to
chemotherapy.
The remaining patient was presented with tumour stage
III and showed neither elevated EBV antibody (IgA-VCA
titre = 5) nor detectable plasma EBV load before and dur-
ing his three subsequent visits. This patient also
responded well to chemotherapy and survived. These
findings confirm earlier reports that patients with persist-
ently detectable plasma EBV DNA had worse survival than
patient with low or undetectable viral DNA following
therapy and that the cell-free EBV DNA was deemed a
good prognosticator of treatment outcome [14,15].
Discussion
To date, this is the first reported study that compares the
plasma levels of EBV DNA, interleukins and growth fac-
tors in consecutive samples of NPC patients before and
after receiving treatment. Untreated NPC patients typi-
cally had elevated IgA-VCA titres although the titres nor-
mally span a broad spectrum. Although the EBV-specific
antibody is known to be an accurate indicator for the pres-
ence of disease, the current data failed to show any associ-
ation of this parameter with the tumour stages. Over the
past few years, cell-free EBV DNA has been increasingly
recognized as a good prognostic marker especially for the
monitoring for disease recurrence in NPC patients [6,14].
As shown in Figure 1, high EBV DNA load was frequently
detected in plasma of untreated NPC patients and a
majority of the patients (34/51) experienced a significant
decline in viral DNA following therapy. Although, regres-
sion analysis did not show any association between
plasma EBV DNA load and the stages of NPC at presenta-
tion, viral DNA load in addition to the IgA-VCA titre was
found to be a good prognosticator for subsequent clinical
event. This was demonstrated in the four of the five
patients who consented to participate in our follow-up
study. Two patients who were presented with stage IIB dis-
ease and had persistently high viral DNA load but waver-
ing IgA-VCA titres during the course of treatments died of
disease progression. On the other hand, two other
patients presented with stages IVB and IIB respectively,
who had persistently high IgA-VCA titres but low and
detectable plasma viral DNA survived. Moreover, favoura-
ble treatment outcome was demonstrated in the remain-
ing patient presented with stage III disease who had
neither detectable plasma EBV DNA nor IgA-VCA titre.
These clinical observations underscore and confirm the
disease prognostic value of cell-free EBV DNA in agree-
ment with the earlier reports by Lo and co-workers [6] and
more recently by Lin and co-workers [15].
The significant reduction in plasma IL-6 level and EBV
DNA load suggest a state of inflammation that was most
probably triggered by EBV infection of tumour cells. This
is in line with a recent study by Chow and co-workers [16]
which shows a correlation between elevated IL-6 levels in
serum as well as in tumour tissues of NPC patients. The
reduction of post-treatment IL-6 level was correlated to a
slight but statistically insignificant increase in IL-10 levels
(Table 1). IL-10 is known for its role in countering and
limiting the extent of inflammation following tissue
injury or infections [17]. Although IL-10 was reported to
be expressed in tissues of primary NPC [8,18], our data
did not indicate any observable differences in the level of
this interleukin in the plasma of NPC patients in compar-
ison to controls. This suggests that the expression of IL-10
is confined to the tumour microenvironment and is not
secreted. IL-10 expression thought to be a mechanism byBMC Cancer 2006, 6:227 http://www.biomedcentral.com/1471-2407/6/227
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which EBV-infected NPC cells counter the local immune
defense by reducing the number of cytotoxic T-cells in the
tumour microenvironment [18]. This hypothesis can be
corroborated with our current data indicating a post-treat-
ment positive correlation between IL-6 and IL-10 levels
where increased level of IL-6 was countered by the propor-
tionate increases in IL-10. IL-10 expression in NPC tissues
[8] and high IL-10 level in serum of PTLD patients [10]
have been shown to be associated with poor survival.
These findings are supported by our current data that indi-
cate a strong correlation between plasma IL-10 level and
EBV DNA load observed in NPC patients following treat-
ment. As has been discussed, high plasma EBV DNA, like
IL-10, is associated with poor prognosis and survival in
NPC.
Of particular interest was the observation that NPC
patients, treated or otherwise, showed a lower level of
plasma TGF-β1 levels as compared to the healthy controls,
suggestive of a protective role for this growth factor in
NPC. Although elevated serum levels of TGF-β1 in NPC
patients has been reported in one study [7], the tumour-
suppressive effects of TGF-β1 has to taken into considera-
tion. Over the recent years, TGF-β has been increasingly
recognized as a potent tumour suppressor in several epi-
thelial and other cell types [19,20]. To date, TGF-β, is
known to for its ability to act as both a tumour suppressor
as well as a tumour promoter. The tumour suppressive
effect is especially pronounced during the early benign
stage but genetic and biochemical alterations during tum-
origenesis may subvert the role of TGF-β to predomi-
nantly tumour promotion. Thus, our data which indicates
a significant decrease in the levels of this growth factor in
NPC patients and a slight recorded increase following
treatment is in favour of the tumour suppressive role of
TGF-β.
Recently, the expression of c-kit and its corresponding lig-
and, SCF, have been shown in NPC cells [11,21]. SCF has
diverse roles in haematopoiesis [22], angiogenesis [23]
and apotosis [24] and affects the growth and differentia-
tion of a vast range of cells. While no significant changes
in SCF levels were observed in the NPC patients before
and after treatment, a strong correlation between the level
of this growth factor and the level of TGF-β1 was noted in
patients after treatment. This is of particular interest as
TGF-β1 is known to counter the cellular proliferative
effects of SCF [25]. A longitudinal study is being planned
to relate plasma TGF-β1 and SCF levels to clinical out-
comes in NPC patients. A corresponding recent study has
indicated that mast cells infiltration into nasal polyp tis-
sue is dependent on SCF secreted by the epithelial cells
[26]. This warrants further investigations on the involve-
ment SCF-dependent cells of the immune system for
example, the mast cells, in the pathogenesis of NPC.
Conclusion
To this end, we conclude from our present data that
plasma EBV DNA load is an excellent indicator for the
presence of NPC and a good prognosticator for disease
progression and clinical outcome. Elevated EBV DNA in
the plasma was shown to be correlated to IL-10 in NPC
patients after treatment. The significant reduction in
plasma EBV DNA load and IL-6 levels in NPC patients fol-
lowing treatment is suggestive of positive response to
treatment. The reduction in plasma TGF-β1 and SCF levels
observed in NPC patients in comparison to controls war-
rants further investigations into the roles of these growth
factors in the pathogenesis of NPC.
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